2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2022
Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2014
HIV Prevention Counseling Intervention Delivered During Routine Clinical Care Reduces HIV Risk Behavior in HIV-Infected South Africans Receiving Antiretroviral Therapy
Fisher JD, Cornman DH, Shuper PA, Christie S, Pillay S, Macdonald S, Ngcobo N, Amico KR, Lalloo U, Friedland G, Fisher WA. HIV Prevention Counseling Intervention Delivered During Routine Clinical Care Reduces HIV Risk Behavior in HIV-Infected South Africans Receiving Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: 499-507. PMID: 25230288, PMCID: PMC4229426, DOI: 10.1097/qai.0000000000000348.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsAntiretroviral therapyClinical care sitesLay counsellorsRisk behaviorsCare sitesRoutine clinical careStandard of careClinical care settingsCounseling interventionHIV careViral suppressionPrimary outcomeHIV statusRoutine careCare counselingCare participantsEffective behavioral interventionsHIV epidemicHIV preventionIntervention participantsCare settingsClinical careBrief interventionInfection incidence
2002
A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298)
Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18: 699-704. PMID: 12167276, DOI: 10.1089/088922202760072311.Peer-Reviewed Original ResearchConceptsCD4 cell countStandard of careD4TViral loadWeek 12Copies/Cell countMedian baseline viral loadPhase II Randomized StudyD4T armDual nucleoside therapyAntiretroviral-naive patientsBaseline viral loadWeeks of monotherapyViral load reductionTreatment of patientsDevelopment of multidrugAntiretroviral-NaiveAntiviral suppressionNaive patientsCD4 cellsImmunologic effectsHIV infectionRandomized studyNucleoside therapy